Format

Send to

Choose Destination
Appl Health Econ Health Policy. 2017 Dec;15(6):805-816. doi: 10.1007/s40258-017-0341-y.

Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.

Author information

1
Population Health Department, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Q4006, Australia.
2
Menzies Health Institute Queensland, Centre for Applied Health Economics, Griffith University, Logan Campus, University Dr, Meadowbrook, Q4131, Australia.
3
Centre for Research Excellence in Sun and Health Queensland, University of Technology, Victoria Park Rd, Kelvin Grove, Brisbane, Q4059, Australia.
4
School of Public Health, The University of Queensland, Brisbane, Australia.
5
Population Health Department, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Q4006, Australia. louisa.gordon@qimrberghofer.edu.au.
6
Centre for Research Excellence in Sun and Health Queensland, University of Technology, Victoria Park Rd, Kelvin Grove, Brisbane, Q4059, Australia. louisa.gordon@qimrberghofer.edu.au.
7
School of Public Health, The University of Queensland, Brisbane, Australia. louisa.gordon@qimrberghofer.edu.au.
8
School of Nursing, Queensland University of Technology, Brisbane, Australia. louisa.gordon@qimrberghofer.edu.au.

Abstract

BACKGROUND:

Skin cancer exerts a large and growing burden on health systems. With new pharmacotherapies for metastatic melanoma now available, a contemporary understanding of the cost burden of melanoma control is warranted.

OBJECTIVE:

To comprehensively assess the healthcare costs of malignant melanoma diagnosis and treatment in Australia, over 3 years after diagnosis.

METHODS:

We developed a decision-analytic model and micro-costing method to estimate the mean cost per patient for melanoma, incorporating all diagnostic and treatment modalities used in Australia (2017 AU$). By using the de-identified 10% sample of Medicare Benefits Scheme, we analysed health service use and supplemented our analyses with published estimates. We took a health system cost perspective, and addressed input uncertainty with sensitivity analyses.

RESULTS:

The mean annual cost per patient for melanoma stage 0/I/II was AU$1681 (US$1175) rising to AU$37,729 (US$26,365) for stage III resectable, and AU$115,109 (US$80,440) for stage III unresectable/IV. Three-year costs for stage III unresectable/IV were AU$187,720. Nationally, the annual estimated cost for treatment of all new cases of in situ and invasive melanomas was AU$201 million (95% CI: AU$187 to AU$216 million). When we included treatments for presumptive melanoma later found to be benign lesions, the estimated annual cost burden reached AU$272 million.

CONCLUSION:

With rapidly rising treatment costs, there is a need to consider a comprehensive melanoma control strategy that includes primary prevention of skin cancers and cost-effective sun protection initiatives.

PMID:
28756584
DOI:
10.1007/s40258-017-0341-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center